Chronic Oral Nicotine Normalizes Dopaminergic Function and Synaptic Plasticity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Primates
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Our recent studies show that chronic oral nicotine partially protects against striatal damage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated nonhuman primates. To identify the cellular changes associated with this protective action, we investigated the effects of nicotine treatment on stimulus-evoked dopamine release, dopamine turnover, and synaptic plasticity in striatum from lesioned and unlesioned animals. Monkeys were chronically (6 months) treated with nicotine in the drinking water and subsequently lesioned with the dopaminergic neurotoxin MPTP (6 months) while nicotine was continued. Nigrostriatal damage increased nicotinic acetylcholine receptor (nAChR)-mediated fractional dopamine release from residual terminals, primarily through changes in α3*/α6* nAChRs. In contrast, fractional receptor-evoked dopamine release was similar to control in unlesioned and lesioned animals with chronic oral nicotine. Long-term nicotine administration also attenuated the enhanced K+-evoked fractional dopamine release from synaptosomes of MPTP-lesioned animals, suggesting that nicotine treatment had a generalized effect on dopaminergic function. This premise was further supported by experiments showing that nicotine dosing decreased the elevated dopamine turnover that occurs after nigrostriatal damage. We next investigated changes in synaptic plasticity with lesioning and nicotine treatment. Nicotine treatment alone enhanced synaptic plasticity by lowering the threshold for long-term depression (LTD) in the corticostriatal pathway. MPTP lesioning led to a loss of LTD, a measure of short-term synaptic plasticity. In contrast, LTD was preserved in nicotine-treated lesioned animals. Thus, the present data show that the disruptions in striatal dopaminergic function after nigrostriatal damage were attenuated with chronic nicotine administration. These cellular alterations may underlie the ability of nicotine to maintain/restore normal function with nigrostriatal damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Reactive Oxygen Species and the Central Nervous System
Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947 · cited 1×
“Elevated dopamine levels have been shown to increase production of reactive oxygen species such as peroxides, superoxides, and hydroxyl radicals and dopamine quinones in residual dopamine terminals (Halliwell, 1992; Hastings et al., 1996; Blum et al., 2001).”
BackgroundPresynaptic nicotinic ACh receptors
Wonnacott, S. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10073-4 · Cited by 1,308 · cited 2×
“Chronic nicotine administration decreases 3*/ 6* nAChRs and is well known to desensitize 4* subtypes, both of which may result in alterations in neuronal transduction mechanisms (Wonnacott, 1997; Giniatullin et al., 2005; Lai et al., 2005; McCallum et al., 2006b).”
BackgroundMelanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301 · cited 2×
“These gradients are associated with distinct patterns of striatal degeneration with nigrostriatal damage, with more severe dopaminergic losses in dorsolateral compared with ventromedial regions and greater declines in the putamen than caudate in animal models and Parkinson’s disease (Parent et al., 1983; Hirsch et al.…”
BackgroundNeuronal nicotinic receptors: from structure to pathology
Gotti, C., & Clementi, F. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.006 · Cited by 970 · cited 2×
“These form pentameric heteromeric receptors that mediate dopamine release in the striatum (Gotti and Clementi, 2004), with 70% release evoked by stimulation of 3*/ 6* nAChRs and the remainder (30%) by 4* receptors (McCallum et al.”
BackgroundTurning of nerve growth cones induced by neurotransmitters
Zheng, J. Q., Felder, M., Connor, J. A., & Poo, M.-M. (1994) · Nature · doi:10.1038/368140a0 · Cited by 580
Desensitization of nicotinic ACh receptors: shaping cholinergic signaling
GINIATULLIN, R., NISTRI, A., & YAKEL, J. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.04.009 · Cited by 357 · cited 1×
“Chronic nicotine administration decreases 3*/ 6* nAChRs and is well known to desensitize 4* subtypes, both of which may result in alterations in neuronal transduction mechanisms (Wonnacott, 1997; Giniatullin et al., 2005; Lai et al., 2005; McCallum et al., 2006b).”
BackgroundNicotine: from molecular mechanisms to behaviour
Wonnacott, S., Sidhpura, N., & Balfour, D. J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.12.002 · Cited by 263 · cited 2×
“Changes in intracellular calcium probably represent an important initial event because nAChRs flux calcium and nAChR-evoked function is calcium dependent (O’Neill et al., 2002; Dajas-Bailador and Wonnacott, 2004; Quik, 2004; Wonnacott et al., 2005).”
BackgroundNicotine addiction: the possible role of functional upregulation
Buisson, B., & Bertrand, D. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01979-9 · Cited by 254 · cited 1×
“Moreover nicotine administration is well known to modulate nAChR function, including evoked dopamine release from striatum, both after acute and chronic exposure (Buisson and Bertrand, 2002; Gentry and Lukas, 2002; Dajas-Bailador and Wonnacott, 2004; Wonnacott et al., 2005).”
BackgroundRegulation of Nicotinic Acetylcholine Receptor Numbers and Function by Chronic Nicotine Exposure
Gentry, C., & Lukas, R. (2002) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007023339184 · Cited by 232
Ryan, R. E., Ross, S. A., Drago, J., & Loiacono, R. E. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703989 · Cited by 188
In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice
Brunzell, D. H., Russell, D. S., & Picciotto, M. R. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01640.x · Cited by 176
Lai, A., Parameswaran, N., Khwaja, M., Whiteaker, P., Lindstrom, J. M., Fan, H., McIntosh, J. M., Grady, S. R., & Quik, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006429 · Cited by 112
Self-citationMcCallum, S. E., Parameswaran, N., Bordia, T., Fan, H., Tyndale, R. F., Langston, J. W., McIntosh, J. M., & Quik, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03646.x · Cited by 44
Self-citation
Cited by
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Calabresi, P., Picconi, B., Parnetti, L., & Di Filippo, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70600-7 · Cited by 338
Synaptic Dysfunction in Parkinson’s Disease
Picconi, B., Piccoli, G., & Calabresi, P. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_24 · Cited by 290
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Nicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
Self-citation
Metadata
- Authors
- Quik, M., Chen, L., Parameswaran, N., Xie, X., Langston, J. W., & McCallum, S. E.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-04-26
- Volume
- 26
- Issue
- 17
- Pages
- 4681-4689
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2073135164
- Cited by
- 77
- References
- 15
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.